Myeloid-derived suppressor cells attenuate the antitumor efficacy of radiopharmaceutical therapy using ⁹⁰Y-NM600 in combination with androgen deprivation therapy in murine prostate tumors.

ABSTRACT:

Rationale

Androgen deprivation therapy (ADT) is pivotal in treating recurrent prostate cancer and is often combined with external beam radiation therapy (EBRT) for localized disease. However, for metastatic castration-resistant prostate cancer, EBRT is typically only used in the palliative setting, because of the inability to radiate all sites of disease. Systemic radiation treatments that preferentially irradiate cancer cells, known as radiopharmaceutical therapy or targeted radionuclide therapy (TRT), have demonstrable benefits for treating metastatic prostate cancer. Here, we explored the use of a novel TRT, ⁹⁰Y-NM600, specifically in combination with ADT, in murine prostate tumor models.

Methods

6-week-old male FVB mice were implanted subcutaneously with Myc-C

SUBMITTER: Muralidhar A 

PROVIDER: S-EPMC11043705 | biostudies-literature | 2024 Apr

REPOSITORIES: biostudies-literature